S-adenosylmethionine inhibits the growth of cancer cells by reversing the hypomethylation status of c-myc and H-ras in human gastric cancer and colon cancer

International Journal of Biological Sciences

Volumn 6, Issue 7, 2010, Pages 784-795

  Luo, Jin ^a   Li, Yan Ni ^b   Wang, Fei ^a   Zhang, Wei Ming ^a   Geng, Xin ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN STOMATOLOGICAL HOSPITAL   (China)

Author keywords

Cancer therapy; Epigenetics; Gastric cancer; Hypomethylation; S adenosylmethionine

Indexed keywords

EID: 78650553499     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.6.784     Document Type: Article

References (43)

1. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer. 2006; 6: 107-116.
2. Laird PW. Principles and challenges of genome-wide DNA methylation analysis. Nat Rev Genet. 2010; 11:191-203.
3. Bhutani N, Brady JJ, Damian M, et al. Reprogramming towards pluripotency requires AID-dependent DNA demethylation. Nature. 2010; 463: 1042-1047.
4. Daura-Oller E, Cabre M, Montero MA, et al. Specific gene hypomethylation and cancer: New insights into coding region feature trends. Bioinformation. 2009; 3: 340-343.
5. Tomita H, Hirata A, Yamada Y, et al. Suppressive effect of global DNA hypomethylation on gastric carcinogenesis. Carcinogenesis. 2010; 31: 1627-1633.
6. Wang Z, Xu J, Geng X, et al. Analysis of DNA methylation status of the promoter of human telomerase reverse transcriptase in gastric carcinogenesis. Arch Med Res. 2010; 41: 1-6.
7. McCabe MT, Brandes JC, Vertino PM. Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res. 2009; 15: 3927-3937.
8. Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res. 2009; 69: 7347-7356.
9. Majid S, Dar AA, Ahmad AE, et al. BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer. Carcinogenesis. 2009; 30: 662-670.
10. Richards KL, Zhang B, Baggerly KA, et al. Genome-wide hypomethylation in head and neck cancer is more pronounced in HPV-negative tumors and is associated with genomic instability. PLoS One. 2009; 4: e4941.
11. Choi JY, James SR, Link PA, et al. Association between global DNA hypomethylation in leukocytes and risk of breast cancer. Carcinogenesis. 2009; 30: 1889-1897.
12. Szyf M, Pakneshan P, Rabbani SA. DNA methylation and breast cancer. Biochem Pharmacol. 2004; 68: 1187-1197.
13. Wolff EM, Byun HM, Han HF, et al. Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet. 2010; 6: e1000917.
14. Luka Z, Mudd SH, Wagner C. Glycine N-methyltransferase and regulation of S-adenosylmethionine levels. J Biol Chem. 2009; 284: 22507-22511.
15. Bale S, Ealick SE. Structural biology of S-adenosylmethionine decarboxylase. Amino Acids. 2010; 38: 451-460.
16. Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology. 2010; 138: 2059-2072.
17. Zhang J, Liu X, Datta A, et al. RCP is a human breast cancer- promoting gene with Ras-activating function. J Clin Invest. 2009; 119: 2171-2183.
18. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene. 2010; 29: 4989-5005.
19. Vanyushin BF. Enzymatic DNA methylation is an epigenetic control for genetic functions of the cell. Biochemistry (Mosc). 2005; 70: 488-499.
20. Turner JD, Pelascini LP, Macedo JA, et al. Highly individual methylation patterns of alternative glucocorticoid receptor promoters suggest individualized epigenetic regulatory mechanisms. Nucleic Acids Res. 2008; 36: 7207-7218.
21. Taghavi N, Biramijamal F, Sotoudeh M, et al. p16INK4a hypermethylation and p53, p16 and MDM2 protein expression in Esophageal Squamous Cell Carcinoma. BMC Cancer. 2010; 10: 138.
22. Calvisi DF, Ladu S, Gorden A, et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest. 2007; 117: 2713-2722.
23. Gonzalo V, Lozano JJ, Muñoz J, et al. Aberrant gene promoter methylation associated with sporadic multiple colorectal cancer. PLoS One. 2010; 5: e8777.
24. Wang X, Lau KK, So LK, et al. CHD5 is down-regulated through promoter hypermethylation in gastric cancer. J Biomed Sci. 2009; 16: 95.
25. Szyf M. The role of DNA hypermethylation and demethylation in cancer and cancer therapy. Curr Oncol. 2008; 15: 72-75.
26. Liu Z, Marquez M, Nilsson S, et al. Incubation with somatostatin, 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cell. Oncol Rep. 2008; 20: 151-154.
27. Chuang JC, Warner SL, Vollmer D, et al. S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther. 2010; 9: 1443-1450.
28. Paliwal A, Vaissière T, Krais A, et al. Aberrant DNA methylation links cancer susceptibility locus 15q25.1 to apoptotic regulation and lung cancer. Cancer Res. 2010; 70: 2779-2788.
29. Pulukuri SM, Estes N, Patel J, et al. Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer. Cancer Res. 2007; 67: 930-939.
30. Ateeq B, Unterberger A, Szyf M, et al. Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo. Neoplasia. 2008; 10: 266-278.
31. Rosty C, Ueki T, Argani P, et al. Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. Am. J. Pathol. 2002; 160: 45-50.
32. Sato N, Fukushima N, Matsubayashi H, et al. Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling. Oncogene. 2004; 23: 1531-1538.
33. Lee YM, Lee JY, Kim MJ, et al. Hypomethylation of the protein gene product 9.5 promoter region in gallbladder cancer and its relationship with clinicopathological features. Cancer Sci. 2006; 97: 1205-1210.
34. Ye L, Li X, Kong X, et al. Hypomethylation in the promoter region of POMC gene correlates with ectopic overexpression in thymic carcinoids. J. Endocrinol. 2005; 185: 337-343.
35. Detich N, Hamm S, Just G, et al. The methyl donor S-Adenosylmethionine inhibits active demethylation of DNA: a candidate novel mechanism for the pharmacological effects of S-Adenosylmethionine. J Biol Chem. 2003; 278: 20812-20820.
36. Zhao Y, Li JS, Guo MZ, et al. Inhibitory effect of S-adenosylmethionine on the growth of human gastric cancer cells in vivo and in vitro. Chin J Cancer. 2010; 29: 752-760.
37. Shukeir N, Pakneshan P, Chen G, et al. Alteration of the methylation status of tumor-promoting genes decreases prostate cancer cell invasiveness and tumorigenesis in vitro and in vivo. Cancer Res. 2006; 66: 9202-9210.
38. Lu SC, Mato JM. S-Adenosylmethionine in cell growth, apoptosis and liver cancer. J Gastroenterol Hepatol. 2008; 23(Suppl1): S73-77.
39. Ramani K, Yang H, Kuhlenkamp J, et al. Changes in the expression of methionine adenosyltransferase genes and S-adenosylmethionine homeostasis during hepatic stellate cell activation. Hepatology. 2010; 51: 986-995.
40. Li TW, Zhang Q, Oh P, et al. S-Adenosylmethionine and methylthioadenosine inhibit cellular FLICE inhibitory protein expression and induce apoptosis in colon cancer cells. Mol Pharmacol. 2009; 76(1):192-200.
41. Li N, Zhang HH, Wang SH, et al. S-adenosylmethionine in treatment of cholestasis after total parenteral nutrition: laboratory investigation and clinical application. Hepatobiliary Pancreat Dis Int. 2002; 1(1):96-100.
42. Silveri MM, Parow AM, Villafuerte RA, et al. S-adenosyl-L-methionine: effects on brain bioenergetic status and transverse relaxation time in healthy subjects. Biol Psychiatry. 2003; 54(8):833-839.
43. Schaller JL, Thomas J, Bazzan AJ. SAMe use in children and adolescents. Eur Child Adolesc Psychiatry. 2004; (5):332-334.